Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.63 |
| ▸ | TGM2 | P21980 | 10/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.62 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.58 |
| ▸ | ITGAV | P06756 | 2/20 | 0.58 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539252 | 0.91 | FOLH1 (0.69) | FOLH1TGM2SIRT2SIRT1MMP2 | |
| SCHEMBL806151 | 0.88 | FOLH1 (0.78) | FOLH1TGM2SIRT2SIRT1ITGB3 | |
| SCHEMBL464715 | 0.88 | FOLH1 (0.78) | FOLH1TGM2SIRT2SIRT1ITGB3 | |
| SCHEMBL4561005 | 0.88 | FOLH1 (0.78) | FOLH1TGM2SIRT2SIRT1ITGB3 | |
| SCHEMBL5841119 | 0.86 | FOLH1 (0.68) | FOLH1TGM2SIRT2SIRT1ITGB3 | |
| SCHEMBL8387978 | 0.85 | FOLH1 (0.65) | FOLH1TGM2SIRT2SIRT1ITGB3 | |
| SCHEMBL27429289 | 0.85 | SIRT2 (0.69) | FOLH1TGM2SIRT2SIRT1ITGB3 | |
| SCHEMBL5841123 | 0.85 | FOLH1 (0.67) | FOLH1TGM2SIRT2SIRT1ITGB3 | |
| SCHEMBL4173691 | 0.84 | FOLH1 (0.72) | FOLH1TGM2SIRT2SIRT1ITGB3 | |
| SCHEMBL4173693 | 0.84 | FOLH1 (0.72) | FOLH1TGM2SIRT2SIRT1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-11965889-B2 | Lysine monomethylated derivative and corresponding antibody and use thereof | PMT BIOLABS INC (CN) | 2024-04-23 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-105273060-B | Lysine single methylation derivatization modified antibody and preparation method thereof | 杭州景杰生物科技股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11965889-B2 | Lysine monomethylated derivative and corresponding antibody and use thereof | KMT5A, PTMS, KDM4D | FOLH1 1805/4885TGM2 1967/4885SIRT2 2020/4885 |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | FOLH1 1818/4885TGM2 2442/4885SIRT2 930/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | FOLH1 1818/4885TGM2 2442/4885SIRT2 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.